Barcelona, Spain, October 6, 2026 / PRNewswire / -- Veeva Systems ( NYSE : VEEV ) Today, it was announced that Veeva DQS ( Data Quality System, Data Quality System) has aggregated and cleaned data from over 1 million participants across more than 1,000 studies, in order to accelerate the provision of clinical trial data and insights that can be used directly for analysis.

Veeva indicates that, with over 500,000 automated queries, Veeva DQS has saved thousands of hours of data verification time for research centers and sponsors.

"For us, an important focus is dealing with the increasing volume of data that comes with the growth in the number of clinical studies," said Vice President Ibrahim Kamstrup - Akkaoui, Novo. "Veeva DQS can help us manage, format, and clean up this data more efficiently, and prepare it for submission."

Veeva DQS supports the next generation of clinical data management and, through a number of improvements, helps to implement the risk-based strategies recommended in regulatory guidelines, including ICH E6 ( R3 ). Veeva indicates that with these innovations, clinical teams can:

• Faster access to high-quality data: Veeva DQS automated data workflow, which classifies and visualizes key data, coordinates risk-based measures throughout the clinical ecosystem, and reduces manual data verification at the same time.
• Implementing risk-based quality management ( RBQM ): Automated data exchange between Veeva DQS and Veeva CTMS can optimize risk-based monitoring. In the event of significant data changes – such as deviations from the plan – it promptly alerts the clinical operations team, and enables the clinical data team to calculate and track key risk indicators ( KRI ) and take corresponding measures.
• Classification using data-driven and user-driven AI: Veeva DQS utilizes artificial intelligence to accelerate the classification of research data and identify its purpose and criticality. Veeva indicates that this helps the system generate reports, lists, or test scripts, among other documents, and provides role-based customized user experiences and work processes.

Veeva DQS Strategic Leader Pavel Burmenko stated: "As the number of data sources increases and the complexity of projects rises, sponsors and contract research organizations (CRO) are utilizing (Veeva DQS) to automate data workflows on a large scale across various research scales. Veeva DQS is ushering in a new era of data management – bringing new dimensions of innovation to the field of clinical data, coordinating risk-based reviews, and elevating the role of data managers to that of strategic partners."

Veeva also recently stated that Veeva Study Builder Agent can directly configure Veeva EDC and Veeva DQS according to the research plan, in order to create studies more quickly and consistently. The company said that more information regarding Study Builder Agent, obtaining SCDM Innovation Award through Veeva DQS, and how biopharmaceutical companies are driving innovation in clinical data will be announced at the Veeva R &D and Quality Summit to be held in Boston from October 20th to 21st. This event is only open to professionals in the life sciences industry.

About Veeva Systems

Veeva provides industry clouds for the life sciences sector, covering applications, agency, data, and consulting services. Veeva is committed to innovation, product quality, and customer success, serving over 1500 clients ranging from the world's largest pharmaceutical companies to emerging biotech startups. As a public interest company, Veeva strives to balance the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, please visit veeva.com / eu.

Veeva Forward-looking Statements

This press release contains forward-looking statements regarding Veeva products and services, as well as the expected results or benefits from using such products and services. These statements are based on the company's current expectations. Actual results may differ significantly from those stated in this press release, and the company has no obligation to update such statements. There are numerous risks that may have an adverse effect on the company's performance, including those disclosed in its 10-Q filing for the fiscal year ending July 31, 2026 (see pages 33 to 34 for a summary of relevant risks), as well as in subsequent filings submitted to the U.S. Securities and Exchange Commission (SEC), which can be viewed at sec.gov.

Contact

Jeremy Whittaker